Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod (SC/IT) + Pembrolizumab in Advanced Melanoma
NCT03084640Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jul 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of vidutolimod in Malignant Melanoma (MM), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 15 days and Treatment-Emergent Adverse Events up to 2.5 years. Started May 2017; status: completed.
02
Drugs
vidutolimod
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03084640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084640.